Cargando…
Update on immune checkpoint inhibitors in gynecological cancers
In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy targeting the immune checkpoint receptors such as cytotoxic T-lymphocyte-a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323287/ https://www.ncbi.nlm.nih.gov/pubmed/28028993 http://dx.doi.org/10.3802/jgo.2017.28.e20 |
_version_ | 1782510000900407296 |
---|---|
author | Heong, Valerie Ngoi, Natalie Tan, David Shao Peng |
author_facet | Heong, Valerie Ngoi, Natalie Tan, David Shao Peng |
author_sort | Heong, Valerie |
collection | PubMed |
description | In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy targeting the immune checkpoint receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell-death 1 (PD-1), and programmed cell-death ligand 1 (PD-L1) have demonstrated clinical activity in a wide variety of tumors, including gynecological cancers. This review will focus on the emerging clinical data on the therapeutic role of immune checkpoint inhibitors, and potential strategies to enhance the efficacy of this class of compounds, in the context of gynecological cancers. It is anticipated that future biomarker-directed clinical trials will provide further insights into the mechanisms underlying response and resistance to immunotherapy, and help guide our approach to designing therapeutic combinations that have the potential to enhance the benefit of immunotherapy in patients with gynecologic cancers. |
format | Online Article Text |
id | pubmed-5323287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-53232872017-03-01 Update on immune checkpoint inhibitors in gynecological cancers Heong, Valerie Ngoi, Natalie Tan, David Shao Peng J Gynecol Oncol Review Article In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy targeting the immune checkpoint receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell-death 1 (PD-1), and programmed cell-death ligand 1 (PD-L1) have demonstrated clinical activity in a wide variety of tumors, including gynecological cancers. This review will focus on the emerging clinical data on the therapeutic role of immune checkpoint inhibitors, and potential strategies to enhance the efficacy of this class of compounds, in the context of gynecological cancers. It is anticipated that future biomarker-directed clinical trials will provide further insights into the mechanisms underlying response and resistance to immunotherapy, and help guide our approach to designing therapeutic combinations that have the potential to enhance the benefit of immunotherapy in patients with gynecologic cancers. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017-03 2016-12-14 /pmc/articles/PMC5323287/ /pubmed/28028993 http://dx.doi.org/10.3802/jgo.2017.28.e20 Text en Copyright © 2017. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Heong, Valerie Ngoi, Natalie Tan, David Shao Peng Update on immune checkpoint inhibitors in gynecological cancers |
title | Update on immune checkpoint inhibitors in gynecological cancers |
title_full | Update on immune checkpoint inhibitors in gynecological cancers |
title_fullStr | Update on immune checkpoint inhibitors in gynecological cancers |
title_full_unstemmed | Update on immune checkpoint inhibitors in gynecological cancers |
title_short | Update on immune checkpoint inhibitors in gynecological cancers |
title_sort | update on immune checkpoint inhibitors in gynecological cancers |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323287/ https://www.ncbi.nlm.nih.gov/pubmed/28028993 http://dx.doi.org/10.3802/jgo.2017.28.e20 |
work_keys_str_mv | AT heongvalerie updateonimmunecheckpointinhibitorsingynecologicalcancers AT ngoinatalie updateonimmunecheckpointinhibitorsingynecologicalcancers AT tandavidshaopeng updateonimmunecheckpointinhibitorsingynecologicalcancers |